X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761125
http://www.koreabiomed.com/news/articleView.html?idxno=14408
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761125
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761125
https://recalls-rappels.canada.ca/en/alert-recall/beovu-brolucizumab-risk-intraocular-inflammation-retinal-vasculitis-andor-retinal
https://www.europeanpharmaceuticalreview.com/news/166232/beovu-shows-positive-results-in-two-year-phase-iii-trial/
https://www.clinicaltrialsarena.com/news/novartis-dme-trial-beovu/
http://www.pharmafile.com/news/599044/novartis-announces-positive-results-phase-iii-trial-beovu
https://www.novartis.com/news/media-releases/novartis-announces-positive-results-from-phase-iii-trials-beovu-diabetic-macular-edema-including-dosing-intervals-16-weeks
https://pharmaphorum.com/news/novartis-halts-three-trials-of-beovu-eye-drug-on-safety-concerns/#:~:text=Novartis%20has%20decided%20to%20halt,every%20two%20or%20three%20months.
https://endpts.com/news-briefing-novartis-eyes-expansion-for-eylea-rival-with-phiii-results-dupixent-obtains-btd-for-eoe/
https://www.novartis.com/news/media-releases/european-medicines-agency-ema-approves-safety-label-update-novartis-beovu#:~:text=Basel%2C%20September%2014%2C%202020%20%E2%80%94,and%20retinal%20vascular%20occlusion1.
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761125
https://www.novartis.com/news/media-releases/us-fda-approves-updated-novartis-beovu-label-include-additional-safety-information
https://endpts.com/boehringer-ingelheim-sharpens-retinal-strategy-scooping-up-dry-amd-drug-from-a-swiss-team-behind-novartis-beovu/
https://www.fiercepharma.com/pharma/despite-covid-19-and-safety-woe-novartis-still-eyes-blockbuster-sales-for-beovu
https://www.biopharmadive.com/news/novartis-beovu-safety-fda-eylea-regeneron/575816/
https://www.fiercepharma.com/pharma/lightning-struck-how-a-safety-alert-shifted-doctor-sentiment-novartis-beovu
https://www.fiercepharma.com/pharma/retinal-society-flags-serious-side-effect-for-novartis-beovu
http://www.pharmatimes.com/news/beovu_bags_eu_approval_in_wet_amd_1326378
https://www.fiercepharma.com/pharma/regeneron-builds-preventative-case-for-eylea-new-2-year-data
https://www.fiercepharma.com/pharma/regeneron-builds-preventative-case-for-eylea-new-2-year-data
http://www.pharmatimes.com/news/five_meds_recommended_in_final_2019_chmp_meeting_1320403
https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-december-2019
https://www.fiercepharma.com/pharma/after-5-blockbuster-nods-2019-novartis-hopes-for-25-more-coming-years
https://www.fiercepharma.com/pharma/regeneron-touts-eylea-countermeasures-as-novartis-goes-aggressive-beovu-launch
https://www.biopharmadive.com/news/regeneron-libtayo-immunotherapy-challenge-merck-lung-cancer/566643/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761125
https://www.fiercepharma.com/marketing/novartis-lines-up-to-challenge-eylea-lucentis-brolucizumab-priority-review
https://www.prnewswire.com/news-releases/novartis-announces-fda-filing-acceptance-and-priority-review-of-brolucizumab-rth258-for-patients-with-wet-amd-300832296.html
https://www.prnewswire.com/news-releases/novartis-announces-fda-filing-acceptance-and-priority-review-of-brolucizumab-rth258-for-patients-with-wet-amd-300832296.html
Market Place
Share 
